Whalesbook
Alembic Pharmaceuticals Limited has begun the mandatory process to transfer shares linked to unclaimed dividends to the Investor Education and Protection Fund (IEPF). This action, mandated by Section 124(6) of India's Companies Act, 2013, applies to dividends that have gone unclaimed for seven consecutive years. The transfer targets dividends from the financial year 2018-2019 onwards, with a strict deadline of August 10, 2026, for shareholders to claim their entitlements. The company officially notified exchanges of this process on May 4, 2026.
This move is a critical regulatory compliance for Alembic Pharma, ensuring proper management of unclaimed corporate assets as per government directives. For shareholders, it serves as a vital reminder: any unpaid dividends must be claimed by the August 10, 2026 deadline. Failure to do so will result in the permanent transfer of these dividends and associated shares to the IEPF, meaning shareholders risk losing them irrevocably.
India's Companies Act, 2013, requires companies to transfer any dividends that remain unclaimed by shareholders for seven consecutive years to the IEPF. This process involves identifying these dividends, notifying shareholders well in advance, and adhering to strict timelines. Shareholders whose dividends or shares have already been transferred to the IEPF can still reclaim them. To do this, they must submit Form IEPF-5 through the Ministry of Corporate Affairs portal. Alembic Pharmaceuticals, like other listed companies, provides information and forms on its website to assist investors with the IEPF claim process.
This procedure is standard practice across the pharmaceutical sector. Major companies such as Granules India, Marksans Pharma, and Jubilant Pharmova also conduct similar transfers of unclaimed dividends to the IEPF, all operating under the same regulatory framework outlined in the Companies Act, 2013. This ensures corporate compliance and maintains accurate shareholder records.
The primary risk for shareholders is missing the August 10, 2026 deadline. After this date, all unclaimed dividends from FY 2018-2019 onwards will be transferred to the IEPF, and shareholders will lose access to these funds and their associated shares. The process of reclaiming funds from the IEPF can also be complex, so it is advisable for shareholders to ensure their Know Your Customer (KYC) details are up-to-date.
Moving forward, investors and stakeholders will monitor the number of claims made before the August 10 deadline. Future disclosures from Alembic Pharma regarding the status of this IEPF transfer, and potentially specific figures on the value or number of shares involved, will also be of interest.